Switch theme
Sign up to access all valuation multiples
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives a majority of its revenue from the United Kingdom and the European Union.
2001
12
LTM Revenue $13.8M
LTM EBITDA -$0.8M
$28.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Futura Medical has a last 12-month revenue (LTM) of $13.8M and a last 12-month EBITDA of -$0.8M.
In the most recent fiscal year, Futura Medical achieved revenue of $18.7M and an EBITDA of $1.8M.
Futura Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Futura Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.8M | XXX | $18.7M | XXX | XXX | XXX |
| Gross Profit | $9.5M | XXX | $13.0M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | -$0.8M | XXX | $1.8M | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | 10% | XXX | XXX | XXX |
| EBIT | -$1.0M | XXX | $1.7M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | -$0.9M | XXX | $1.7M | XXX | XXX | XXX |
| Net Margin | -7% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Futura Medical's stock price is GBP 0 (or $0).
Futura Medical has current market cap of GBP 28.0M (or $37.5M), and EV of GBP 21.4M (or $28.7M).
See Futura Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.7M | $37.5M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Futura Medical has market cap of $37.5M and EV of $28.7M.
Futura Medical's trades at 1.5x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Futura Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Futura Medical has a P/E ratio of -40.5x.
See valuation multiples for Futura Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $37.5M | XXX | $37.5M | XXX | XXX | XXX |
| EV (current) | $28.7M | XXX | $28.7M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | -35.4x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | -28.2x | XXX | 17.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -40.5x | XXX | 21.6x | XXX | XXX | XXX |
| EV/FCF | -10.3x | XXX | -16.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFutura Medical's last 12 month revenue growth is -51%
Futura Medical's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.9M for the same period.
Futura Medical's rule of 40 is -271% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Futura Medical's rule of X is -132% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Futura Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -51% | XXX | -39% | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 387% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -271% | XXX | -41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -132% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Futura Medical acquired XXX companies to date.
Last acquisition by Futura Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Futura Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Futura Medical founded? | Futura Medical was founded in 2001. |
| Where is Futura Medical headquartered? | Futura Medical is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Futura Medical have? | As of today, Futura Medical has 12 employees. |
| Who is the CEO of Futura Medical? | Futura Medical's CEO is Mr. James Henry Barder. |
| Is Futura Medical publicy listed? | Yes, Futura Medical is a public company listed on LON. |
| What is the stock symbol of Futura Medical? | Futura Medical trades under FUM ticker. |
| When did Futura Medical go public? | Futura Medical went public in 2003. |
| Who are competitors of Futura Medical? | Similar companies to Futura Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Futura Medical? | Futura Medical's current market cap is $37.5M |
| What is the current revenue of Futura Medical? | Futura Medical's last 12 months revenue is $13.8M. |
| What is the current revenue growth of Futura Medical? | Futura Medical revenue growth (NTM/LTM) is -51%. |
| What is the current EV/Revenue multiple of Futura Medical? | Current revenue multiple of Futura Medical is 2.1x. |
| Is Futura Medical profitable? | Yes, Futura Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Futura Medical? | Futura Medical's last 12 months EBITDA is -$0.8M. |
| What is Futura Medical's EBITDA margin? | Futura Medical's last 12 months EBITDA margin is -6%. |
| What is the current EV/EBITDA multiple of Futura Medical? | Current EBITDA multiple of Futura Medical is -35.4x. |
| What is the current FCF of Futura Medical? | Futura Medical's last 12 months FCF is -$2.8M. |
| What is Futura Medical's FCF margin? | Futura Medical's last 12 months FCF margin is -20%. |
| What is the current EV/FCF multiple of Futura Medical? | Current FCF multiple of Futura Medical is -10.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
